Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gynecologic 3

Conditions

Ovarian Neoplasms 2573Uterine Cervical Neoplasms 1693Endometrial Neoplasms 1012Fallopian Tube Neoplasms 730Carcinoma, Ovarian Epithelial 681Breast Neoplasms 676Neoplasms 436Carcinoma, Non-Small-Cell Lung 379Colorectal Neoplasms 372Stomach Neoplasms 302Pancreatic Neoplasms 302Uterine Cervical Dysplasia 273Prostatic Neoplasms 262Lung Neoplasms 250Melanoma 247Neoplasm Metastasis 216Peritoneal Neoplasms 197Carcinoma, Renal Cell 193Sarcoma 190Head and Neck Neoplasms 189Urinary Bladder Neoplasms 187Esophageal Neoplasms 187Recurrence 185Triple Negative Breast Neoplasms 181Uterine Neoplasms 176Vulvar Neoplasms 173Squamous Cell Carcinoma of Head and Neck 168Colonic Neoplasms 162Papillomavirus Infections 153Small Cell Lung Carcinoma 128

Interventions

temsirolimus 1Sorafenib 1Sirolimus 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Recurrent Uterine Sarcoma × Gynecologic × Clear all
NCT00075400 2019-07-24

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

NCT01061606 2016-11-09

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Terminated
8 enrolled 6 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

NCT00238121 2015-11-20

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡